Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified BFM Backbone Therapy for Chinese Children or Adolescents With Newly Diagnosed Lymphoblastic Lymphoma
NCT02845882Phase 3Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Jan 2016
- Primary completion
- Dec 2023
- Modality
- DNA Intercalators/Alkylators, Therapeutic Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of pegaspargase, daunorubicin, prednisone, vincristine, cytarabine in lymphoblastic lymphoma (LL), sponsored by Children's Oncology Group. Started Jan 2016; status: active, not recruiting.
02
Drugs
pegaspargasedaunorubicinprednisonevincristinecytarabine
03
Conditions
lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT02845882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02845882.